测定B淋巴细胞的简易方法鼠红细胞玫瑰花测定方法及其在肿瘤临床上的应用

 人体的免疫淋巴细胞基本分T及B细胞.一般应用EAC、EA玫瑰花或莹光抗体等测定B细胞,但其方法较复杂.自从1974年Stathopoulos和Elliot发现鼠红细胞(简称MR BC)能与慢性淋巴性白血病患者的淋巴细胞自发地形成玫瑰花以来,国外有些作者对鼠玫瑰花(简称MERFC)做了不少工作,证实MERFC是B细胞的一个亚族,可作为鉴定B细胞的一种方法.     

食管癌、贲门癌患者外周血CD+8NKT细胞活化受体NKG2D及其分泌性配体sMICA检测的临床意义

Objective To evaluate the clinical diagnostic application and operative efficacy of the expression of NKG2D in peripheral blood CD+8 NKT cell and its ligand sMICA in patients with esophageal or cardiac carcinoma.Methods The peripheral blood NKG2D positive CD+8 NKT cell percentage was concomitantly determined by flow cytometry in 53 preoperative patients including 29 postoperative patients with esophageal or cardiac carcinoma and 30 healthy controls.The serum sMICA was determined by ELISA.Results The peripheral blood NKG2D positive CD+8 NKT cell percentage in patients was significantly lower than that in controls [(77.632±8.972) % vs (89.053±6.515) %] (t = -6.113,P ＜0.05); with stage Ⅱ,Ⅲ,Ⅳ,it decreased significantly in order (F = 99.251,P ＜0.01);with lymph node metastasis lower than that without lymph node metastasis (t = -10.384,P ＜0.01); squamous carcinoma was higher than adenocarcinoma (t =9.899,P ＜0.01); postoperative was significantly higher than preoperative (t =-4.319,P ＜0.01).The level of serum sMICA in patients was significantly higher than that in controls [(326.28±85.407) pg/ml vs (210.00±92.560) pg/ml](t =7.292,P ＜0.01); with stage Ⅱ,Ⅲ,Ⅳ,it increased significautly in order (F =63.355,P ＜0.01); with lymph node metastasis higher than that without lymph node metastasis (t =7.770,P ＜0.01); squamous carcinoma was lower than adenocarcinoma (t =-7.593,P＜0.01); postoperative was significantly lower than preoperative (t =7.027,P ＜0.01).Serum sMICA could inhibit peripheral blood CD+8 NKT cell activation receptor NKG2D (F =142.773,P ＜0.05),determination coefficient R2 = 0.7368.Conclusion The level of peripheral blood CD+8NKT cell activation receptor NKG2D and serum sMICA in patients could be an assistant indicator for     

乳癌患者的免疫功能及术后免疫治疗

<正> 乳癌是我国女性常见的恶性肿瘤。进一步了解乳癌患者的免疫状态,如何应用免疫治疗,以提高术后生存率,延长生存期,乃是乳癌研究的一个新课题。现将我们在这方面进行的初步工作小结如下:     

贲门癌患者外周血CD4+CD25hiCD127low调节性T细胞水平及其临床意义

Objective To analyse the dysfunction of immunity and clinical significance in patients with cardiac cancer.Methods The level of CD4+ CD25hi CD127low Treg cells were detected by flow cytometry (FCM),and serum IL-10 and TGF-β1 levels were determined by enzyme linked immunosorbent assay (ELISA) kit in 56 patients with cardiac cancer.15 healthy volunteers were tested as normal controls.The clinical data of each patient were collected and analyzed. Results There was a significantly higher percentage of CD4+ CD25hi CD127low Treg cells in patients with cardiac cancer (5.73±1.56)% than that (4.45±1.06)% of healthy volunteers (P<0.01).The IL-10 and TGF-β1 levels in the serum of patients with cardiac cancer were also significantly higher than that of healthy volunteers (P<0.05).There was a positive correlation between levels of IL-10.TGF-β1 and the levels of CD4+ CD25hi CD127low Treg cells.The number of CD4+ CD25hi CD127low regulatory T cells in the peripheral blood of cardiac cancer patients were significantly correlated with clinical stages and metastasis lymph node.Conclusion The CD4+ CD25hi CD127low Treg cells in the peripheral blood of cardiac cancer patients is significantly increased in comparison with that in healthy volunteers,and was also correlated with different stages.The abnormal levels of CD4+ CD25hi CD127low Treg cells may be related to tumor progression in patients with cardiac cancer.     

恶性血液系统肿瘤自体干细胞移植前后免疫功能的变化

高剂量的放化疗加上自体造血干细胞移植 (AHSCT)已大大地提高了各种恶性血液系肿瘤的疗效 ,并已成为其根治性治疗的重要措施之一。然而 ,大剂量化疗不只杀伤肿瘤细胞 ,而且对患者的免疫功能也有严重的损伤。但有关大剂量化疗后免疫功能的报道不多 ,现将我们近几年来有关这方面的工作报道如下。1　对象与方法1. 1　对象　 10例恶性淋巴瘤 (其中NHL7例 ,HD3例 ) ,1例恶性多发性骨髓瘤。男性 6例 ,女性 5例。年龄 10岁～5 8岁 ,中位年龄为 30岁。淋巴瘤分期 : A2例 , A4例 , B4例。正常对照 30例。1.2　测定方法　 1)淋巴细胞转化试验 :3…     

贲门癌患者外周血CD+4 CDhi25 CDlow127 调节性T细胞水平及其临床意义

 目的　探讨贲门癌患者的免疫功能异常及其临床意义。方法　采用流式细胞术（FCM）和酶联免疫吸附（ELISA）方法分别检测 56例贲门癌患者、15名健康人外周血中CD+4 CDhi25 CDlow127 调节性T细胞（Treg细胞）和血清IL-10、TGF-β1水平,结合临床资料进行分析。结果　56例贲门癌患者外周血中CD+4 CDhi25 CDlow127 Treg细胞占CD+4淋巴细胞的比例为（5.73±1.56）%,与健康对照组的（4.45±1.06）%相比,差异有统计学意义（P＜0.01）;血清中IL-10和TGF-β1含量均明显高于健康对照（P＜0.05）。贲门癌患者外周血CD+4 CDhi25 CDlow127 Treg细胞水平与血清IL-10和TGF-β1含量呈正相关。贲门癌患者外周血CD+4 CDhi25 CDlow127 Treg 细胞数量与患者临床分期、淋巴结转移有关。结论　贲门癌患者外周血中CD+4 CDhi25 CDlow127 Treg细胞表达增高,与临床分期有关,提示Treg水平异常与贲门癌的发生发展密切相关。     

癌症患者血清与淋巴细胞因素的析因分析

应用析因设计,对20例癌患者的血清及淋巴细胞在淋转抑制中的作用,进行了分析。结果表明:(1) 癌患者的血清具有一定的免疫抑制作用;(2) 癌患者的淋巴细胞对PHA的反应能力,也明显低于正常对照;(3) 在癌患者的免疫能力受损的机制中,淋巴细胞的作用较之血清更为重要。     

乳腺癌患者的细胞免疫功能

 癌症患者的免疫功能与癌的发生、发展及预后有着密切关系,深入了解乳腺癌患者的免疫功能及各种主要治疗措施对它的影响显然是必要的。现将我们在这一方面的工作小结如下。材料及方法(一)对象:乳腺癌患者90人,均为女性,除9例晚期乳癌患者外,其他皆经手术及病理证实,平均年龄48.3±8.5岁。     

大肠癌患者细胞因子的变化及其临床意义

目的观察不同治疗阶段大肠癌患者T淋巴细胞亚群CD4^＋细胞中,Th1／Th2类因子水平的变化,为大肠癌的生物治疗提供依据。方法分离外周血淋巴细胞,经刺激增加细胞内因子表达,荧光标记特异性抗细胞因子单克隆抗体,特异性抗原抗体结合,用流式细胞术分析、测定特异性细胞因子表达水平。结果大肠癌患者在不同的治疗阶段,Th1类因子的变化较明显,差异均有统计学意义;Th2类因子变化无显著性。IFN-γ／IL-4的比值变化只在生物治疗前后差异有统计学意义。结论大肠癌患者在不同治疗阶段,Th1类因子水平的变化对生物治疗具有明显的指导意义;Th2类因子水平无指导意义。其中IFN-γ／IL-4比值的变化在生物治疗中具有较好的指导性,合理的生物治疗可逆转Th1／Th2因子的抗肿瘤抑制作用。     

贲门癌患者外周血CD4+CD25hiCD127low调节性T细胞水平及其临床意义

目的 探讨贲门癌患者的免疫功能异常及其临床意义.方法 采用流式细胞术(FCM)和酶联免疫吸附(ELISA)方法分别检测56例贲门癌患者、15名健康人外周血中CD4+CD25hiCD127lowc调节性T细胞(Treg细胞)和血清IL-10、TGF-β1水平,结合临床资料进行分析.结果 56例贲门癌患者外周血中CD4+CD25hiCD127lowTreg细胞占CD4+淋巴细胞的比例为(5.73±1.56)%,与健康对照组的(4.45±1.06)%相比,差异有统计学意义(P<0.01);血清中IL-10和TGF-β1含量均明显高于健康对照(P<0.05).贲门癌患者外周血CD4+CD25hiCD127low Treg细胞水平与血清IL-10和TGF-β1含量呈正相关.贲门癌患者外周血CD4+CD25hiCD127low Treg细胞数量与患者临床分期、淋巴结转移有关.结论 贲门癌患者外周血中CD4+CD25hiCD127low Treg细胞表达增高,与临床分期有关,提示Treg水平异常与贲门癌的发生发展密切相关.